



Colorectal Cancer Research at NIH

This study will determine whether Pexastimogene Devacirepvec (Pexa-Vec), given in combination with Durvalumab, will cause tumors to shrink. Pexa-Vec is a vaccine used to help boost the immune system to attack and destroy the cancer cells in patients. Durvalumab targets PDL-1, a protein found on tumor cells that contributes to the tumors avoidance of the immune system.

Study Design:

- Physical examination and questionnaire
- Imaging assessments (computed tomographic scan (CT) or magnetic resonance imaging (MRI))
- Study treatment will be divided into cycles each lasting approximately 28 days

Eligibility:

- Patients must have progressed on, been intolerant of, or refused prior treatment
- Patients must have at least one focus of metastatic disease
- Patient able to provide a tumor sample from a previous surgery to confirm patient's diagnosis. If a sample is not available, patient will need to have a biopsy of your tumor

FOR MORE INFORMATION: Office of Patient Recruitment

Toll Free: 800-411-1222

800-877-8339 TTY / ASCII

Email: PRPL@cc.nih.gov

Online: <https://go.usa.gov/xpvP3>

Refer to study # 17-C-0092

*The NIH Clinical Center,
America's Research Hospital
located in Bethesda, MD
Medical Center Metro Stop (red line)*



**NATIONAL
CANCER
INSTITUTE**